Downregulation of miR-342 is associated with tamoxifen resistant breast tumors
Molecular Cancer, 2010 Background Tumor resistance to the selective estrogen receptor modulator tamoxifen remains a serious clinical problem especially in patients with tumors that also overexpress HER2.
Richer Jennifer K +6 more
doaj +1 more source
The relationship between oestrogen receptor-alpha phosphorylation and the tumour microenvironment in patients with primary operable ductal breast cancer [PDF]
, 2017 Aims: Although the role of phosphorylation of oestrogen receptor (ER) at serines 118 (p-S118) and 167 (p-S167) has been studied, the relationship between p-S118, p-S167 and the tumour microenvironment in ER-positive primary operable ductal breast ...
Arnold +38 more
core +1 more source
Life, 2022 NCOR2 is a co-repressor for estrogen receptor (ER) and androgen receptor (AR). Our group previously identified a novel splice variant of NCOR2, BQ323636.1 (BQ), that mediates tamoxifen resistance via interference of NCOR2 repression on ER.
Ho Tsoi +6 more
doaj +1 more source
Gains in Power from Structured Two-Sample Tests of Means on Graphs [PDF]
, 2010 We consider multivariate two-sample tests of means, where the location shift between the two populations is expected to be related to a known graph structure.
Dudoit, Sandrine +2 more
core +7 more sources
GPER-induced signaling is essential for the survival of breast cancer stem cells. [PDF]
, 2020 G protein-coupled estrogen receptor-1 (GPER), a member of the G protein-coupled receptor (GPCR) superfamily, mediates estrogen-induced proliferation of normal and malignant breast epithelial cells.
Chan, Yu-Tzu +12 more
core +2 more sources
Cholesterol metabolism and resistance to tamoxifen
Current Opinion in Pharmacology, 2012 The oncoprotein MUC-1 was shown to upregulate the transcription of genes encoding cholesterol and lipid metabolic enzymes and correlated with a resistance to Tamoxifen (Tam) despite the presence of estrogen receptor α in breast cancer tumors. The importance of this observation is supported by molecular studies on Tam suggesting two additional ...
Poirot, Marc +2 more
openaire +2 more sources
Translational Oncology, 2020 Tamoxifen is a successful endocrine therapy drug for estrogen receptor–positive (ER+) breast cancer. However, resistance to tamoxifen compromises the efficacy of endocrine treatment.
Yijie Fu +6 more
doaj +1 more source
Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement [PDF]
, 2015 Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and the third cause of cancer death worldwide. Chronic hepatitis due to HBV and HCV infection are two major risk factors for HCC worldwide.
Cuestas, María Luján +2 more
core +1 more source
LncRNA ATXN8OS enhances tamoxifen resistance in breast cancer [PDF]
Open Medicine, 2020 Abstract Background Tamoxifen (TAMR) resistance remains a massive obstacle for breast cancer (BC) management. The precise parts of long non-coding RNA ataxin 8 opposite strand (ATXN8OS) in BC TAMR resistance have not been defined. Methods
Zhang Hongkai +3 more
openaire +3 more sources
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer [PDF]
, 2018 Background Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER+) breast cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth factor pathways, circumventing ...
A Carracedo +43 more
core +6 more sources